Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy

Furness, Susan; Glenny, Anne Marie; Worthington, Helen V; Pavitt, Sue; Oliver, Richard; Clarkson, Jan E; Macluskey, Michaelina; Chan, Kelvin K.; Conway, David I.

doi:10.1002/14651858.cd006386.pub3

Cited by 101 publications

(60 citation statements)

References 283 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conventional treatment for OCC includes surgery, radiotherapy, and chemotherapy. OCC surgical management often can lead to severe morbidity due to disfiguring and functional side effects (Furness et al, 2011). Surgery combined with chemotherapy and radiotherapy can improve overall survival, particularly in patients with advanced oral cancers.…”

Section: Oral Cancer Recurrence and Therapeutic Modalitiesmentioning

confidence: 99%

Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches

Silva¹,

Hier²,

Mlynarek³

et al. 2012

Front. Pharmacol.

112

115

View full text Add to dashboard Cite

Oral cavity cancer (OCC) is associated with high incidence of loco-regional recurrences, which account for the majority of treatment failures post-surgery and radiotherapy. The time-course of relapse manifestation and metastasis are unpredictable. Relapsed OCC represents a major clinical challenge in part due to their aggressive and invasive behaviors. Chemotherapy remains the only option for advanced OCC whenever salvage surgery or re-irradiation is not feasible, but its efficacy is limited as a result of the drug resistance development. Alternatives to use of different permutations of standard cytotoxic drugs or combinations with modulators of drug resistance have led to incremental therapeutic benefits. The introduction of targeted agents and biologics against selective targets that drive cancer progression has opened-up optimism to achieve superior therapeutic activity and overcome drug resistance because, unlike the non-selective cytotoxic, the target can be monitored at molecular levels to identify patients who can benefit from the drug. This review discusses the multifactorial aspects of clinical drug resistance and emerging therapeutic approaches in recurrent OCC, emphasizing recent advances in targeted therapies, immunotherapy, and potential relevance of new concepts such as epithelial-mesenchymal transition and cancer stem cell hypothesis to drug resistance.

show abstract

Section: Oral Cancer Recurrence and Therapeutic Modalitiesmentioning

confidence: 99%

Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches

Silva¹,

Hier²,

Mlynarek³

et al. 2012

Front. Pharmacol.

112

115

View full text Add to dashboard Cite

show abstract

“…While inspection of the oropharyngeal cavity for lesions is simpler and less invasive than at other sites of the gut, many cancers are still not detected until they are at an advanced stage of progression (Ford & Farah, 2013). Treatment (normally aggressive surgery, chemotherapy or radiotherapy) often results in a loss of normal oral processing function and greatly reduced quality of life (Bessell et al, 2011;Furness et al, 2011;Glenny et al, 2010;Pavitt et al, 2007).…”

Section: Oropharyngeal Conditionsmentioning

confidence: 99%

The impact of dietary fibre intake on the physiology and health of the stomach and upper gastrointestinal tract

Brownlee

2014

Bioactive Carbohydrates and Dietary Fibre

View full text Add to dashboard Cite

Mastication Swallowing Saliva Gastric juice Upper gastrointestinal cancer a b s t r a c t This review is the first in a series of three articles considering how different types of dietary fibre may affect how the gut functions and gut health. This first review will focus on the impact of dietary fibre intake on the upper gastrointestinal tract (i.e. the mouth, oesophagus and stomach). While a larger body of evidence links fibre intake to bowel health and disease, it is apparent that the presence of fibre, whether as an added ingredient in foods, or as an integral part of the structure of plant foods, also plays key roles on oral and gastric secretions and upper gut motility. These actions are possibly modulated through fibre's effects on the physicochemical properties of luminal contents in the gut.The major physiological functions of the mouth, oesophagus and stomach are discussed and recent evidence relating dietary fibre intake to these actions is introduced. A summary of evidence linking habitual dietary fibre consumption to major mucosal diseases of the upper gastrointestinal tract is also provided.

show abstract

“…More than 90% of these malignancies are squamous cell carcinomas, and approximately 60% of patients will present with locoregionally advanced (LRA), nonmetastatic disease (AJCC stage III/IV). Although historically surgical resection has been the cornerstone of treatment for LRA head and neck squamous cell carcinoma (HNSCC), more recent multimodality therapies that may include surgery, radiotherapy and systemic therapy (chemotherapy or cetuximab) have become standards of care [3,4].…”

Section: Abstract: Carboplatin • Cisplatin • Head and Neck Squamous Cmentioning

confidence: 99%

In squamous cell head and neck cancer: which platinum, how much and how often?

Nwizu

Adelstein

2014

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma is the fifth most common cancer worldwide. Patients who present with locally advanced disease are usually treated with a combined modality approach, often including chemotherapy, and frequently using the platinum agents cisplatin or carboplatin. In locally advanced head and neck squamous cell carcinoma, carboplatin and cisplatin have both been found to produce a survival benefit when added to radiation therapy. Although it appears that cisplatin may be more active, carboplatin is better tolerated. Cisplatin has been given concurrently with radiation every 3 weeks, weekly or daily. There have been no prospective trials comparing the different cisplatin dose schedules, but a dose of 100 mg/m(2) administered every 3 weeks on days 1, 22 and 43 with concurrent standard fractionation radiation therapy is the most widely used and tested regimen. The required total dose of cisplatin is also not known, although a necessary dose threshold of 200 mg/m(2) has been suggested.

show abstract

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy

Cited by 101 publications

References 283 publications

Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches

Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches

The impact of dietary fibre intake on the physiology and health of the stomach and upper gastrointestinal tract

In squamous cell head and neck cancer: which platinum, how much and how often?

Contact Info

Product

Resources

About